ABSTRACT
Depressed patients who receive electroconvulsive therapy (ECT) are frequently prescribed lorazepam to treat insomnia; doses used range from 1-3 mg nightly (Sackeim et al.,1993) . The preference for lorazepam is possibly due to its relatively short mean half-life of 12 hrs, in comparison with 25 hrs for nitrazepam and 30 hrs for diazepam (Psychotropic Drug Guidelines Subcommittee, 1995) . Since benzodiazepine drugs have anticonvulsant properties, a valid concern is that the co-prescription of such hypnotic drugs may compromise the therapeutic effects of ECT; this concern is particularly relevant to ECT with unilateral electrode placement (Pettinati et al., 1990) . There is no consensus on the coprescription of other agents with sedative properties, such as the tricyclic antidepressant drugs. On the one hand, the tricyclic drugs may augment the antidepressant action of ECT; on the other hand, these drugs may unfavourably prolong the ECT seizure duration and predispose to increased cognitive adverse affects through this mechanism and through central anticholinergic actions (Andrade,1990; Pritchett et al.,1993) .
Zopicione is a cyclopyrrolone hypnotic agent which acts on the benzodiazepine-GABA receptor complex but not at the same site as the benzodiazepine drugs (Byrnes et al.,1992) ; therefore, zopicione may conceivably have a lesser impact on the ECT seizure. Furthermore, zopicione has a short mean half-life of 5 hours (Psychotropic Drug Guidelines Subcommittee, 1995) . Therefore, at the time ECT is administered, the drug would have been substantially washed out of the body; this could further reduce its effects upon the ECT seizure.
In view of these conjectures, the present study sought to examine the effect of zopiclone on one aspect of the ECT seizure , motor seizure duration. For ethical reasons, an animal model was utilized.
MATERIAL AND METHOD
Adult, male, Sprague-Dawley rats were housed 3/cage and were provided free access to tap water and standard laboratory diet. In each cage, rats received zopiclone in solution, lorazepam in solution, or distilled water alone. Zopiclone was administered in the dose of 1.5 mg/kg, while lorazepam was administered in the dose of 0.2 mg/kg. These doses were selected after careful preliminary studies on rats demonstrated satisfactory and comparable sedation approximately 40 minutes after drug administration. These doses also maintained the proportion of 7.5 mg (zopiclone) to 1 mg (lorazepam); these are the conventional doses at which the drugs are prescribed, to the average patient, for hypnosis. Both drugs were administered by slow, intra-oral syringing, and volumes of administration were comparable.
A single electroconvulsive shock (ECS) was administered to each rat using earclip electrodes coated with electrode jelly. ECS was given 30 minutes after drug administration, using the Malar Medisystems (Cochin) constant current, unipolar brief-pulse (ECT) device. The administered charge was 30 mC, with stimulus settings of 0.5A for current intensity, 1 msec for pulse width, 60 Hz for pulse frequency, and 1 sec for stimulus train duration.
Motor seizure duration was assessed by an experienced observer who used a stopwatch. The beginning of the seizure was defined as the onset of delivery of the ECS stimulus. Two definitions of endpoint were employed. The endpoint of the motor seizure was defined as the termination of synchronous and symmetrical convulsive movements; work in our and other laboratories has demonstrated that this coincides fairly satisfactorily with the endpoint of the EEG seizure. The endpoint of the total motoric phase was defined as the cessation of all movements; this includes a post-ictal phase of random motor activity, sometimes termed as the running phase' (Fochtmann,1999; personal communication) . While the theoretical significance of the running phase remains to be clarified, it is emphasized that the rat is unconscious until long after both these endpoints are attained.
RESULTS
Seizure duration and motoric phase data are presented in the 
DISCUSSION
Agents that abbreviate the ECT seizure may impact negatively on the efficacy of ECT; a seminal observation was that lidocaineabbreviated seizures are subtherapeutic (Cronholm & Ottosson,1960) . Although it is currently realized that seizure duration is not an ideal measure of ECT, it is nonetheless the measure that is most readily accessible to clinicians (Andrade,1997) . Bedside recommendations for ECT seizure adequacy therefore continue to prescribe minimum durations for the motor and/or electroencephalographic seizures (American Psychiatric Association, 1990; Scott & Lock, 1995) .
This study was conducted with the expectation that zopiclone might have a lesser impact on ECT seizure duration because it does not act upon the same site as do the benzodiazepine drugs, and because it has not been reported to have clinically significant anticonvulsant properties (Goa & Heel, 1986) . However, it was observed that while attenuation of seizure duration by lorazepam did not attain statistical significance, that with zopiclone did. Thus, zopiclone may be even more detrimental to ECT efficacy than benzodiazepines.
These findings were not totally unexpected. In animal models, zopiclone was shown to inhibit seizures induced by electroconvulsive shocks and by pentylenetetrazol; the anticonvulsant potency of zopiclone in these studies was greater than that of chlordiazepoxide and nitrazepam (Julou et al.,1983; Goa & Heel,1986) . However, no literature was available on a direct comparison between zopiclone and lorazepam, with reference to the seizure duration measures addressed in the present investigation. The present study was therefore heuristic and necessary.
Neither zopiclone nor lorazepam attenuated the total motoric duration. However, this phase includes a post-ictal period of random motoric movements that bear uncertain relevance to the intensity of the ECS seizure (Fochtman,1999; personal communication) , therefore, the absence of impact on the motoric phase is of uncertain theoretical importance, but nonetheless merits scrutiny in future research.
From simple, linear, mathematical modelling based on drug half-lives, some additional considerations are warranted. If ECT is scheduled 12 hrs after hypnotic drug treatment, approximately 75-85% of the previous night's zopiclone dose, and 50% of the previous night's lorazepam dose, would have been washed out of the body. These considerations apply to zopiclone in both single and daily dosing situations. With lorazepam, after 2-3 nights of treatment, attainment of steady-state levels would result in only 35% of the drug being washed out by the time the morning's ECT is scheduled. It therefore makes sense to prefer zopiclone if the scheduling of ECT is such that sufficient time has elapsed for zopiclone to have been substantially washed out of the body; otherwise, lorazepam may remain the hypnotic of choice until better alternatives, such as Zolpidem, become available in India. 
